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Background/aim: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are 2 common rheumatic diseases that are frequent
causes of disability. In this descriptive study, demographic, clinical, and laboratory findings of patients with RA and AS being followed
in a tertiary care center in Turkey were reported.
Materials and methods: The patient data of 45 RA and 45 AS cases were collected retrospectively from electronic medical records.
Demographic findings, clinical and laboratory assessments of disease activity, drugs used for the treatment, and effect on quality of life
of patients with RA and AS were analyzed.
Results: In RA patients, 27% had mild, 44% had moderate, and 29% had severe disease and 25% of the patients had satisfactory
functional state. In AS patients, the mean Bath Ankylosing Spondylitis Disease Activity Index score was 4.6 ± 2.3 and 64% had active
disease. Sixteen percent of the patients with AS reported satisfactory functional state. In RA cases, the highest percentage of patients
were treated with biological agents. In AS cases, 24% of patients were treated with NSAIDs and 22% received biological agents.
Conclusion: In our tertiary care center, the majority of patients with RA and AS had active disease with unsatisfactory functional states.
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1. Introduction
Rheumatoid arthritis (RA) and ankylosing spondylitis
(AS) are 2 common rheumatic diseases that are frequent
causes of disability. RA affects almost 1% of the population
worldwide and is more prominent in women than men
with a ratio of 3.6 to 1.7 (1). The American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) 2010 classification criteria for rheumatoid
arthritis represent an improvement in the diagnostic
approach to the disease and promote the goal of early
intervention to improve outcomes (2).
AS, the prototype disease in the spectrum of
spondyloarthritides, has a prevalence of 0.5% in the
general population with a male-to-female ratio of 2:1 to
3:1 (3).
In a recent study conducted in western Turkey, the
prevalence rate was 0.12% for AS and 0.32% for RA (4).
This study analyzed the demographic data, clinical and
laboratory parameters of disease activity, and drugs used
in the treatment of RA and AS patients being followed in a
tertiary care center in Turkey.
* Correspondence: ozlemonur@hotmail.com

2. Materials and methods
2.1. Study design and patients
This was a retrospective study done on patients with RA
and AS, seen between January 2012 to April 2013 in a
university hospital’s Department of Physical Medicine and
Rehabilitation. The study was approved by the institutional
ethics committee. The patients’ data were collected from
electronic medical records. The routine clinical forms used
by the Department of Physical Medicine and Rehabilitation
for RA and AS patients were included in the data collection.
The medical records of a total of 90 patients (45 with each
diagnosis) were included in this study. Incomplete data or
forms of AS or RA patients were excluded.
2.2. Rheumatoid arthritis
The 2010 ACR/EULAR classification criteria for RA
were used for the diagnosis of RA (2). The RA forms
included age, sex, duration of the disease, drugs used
for the treatment of RA, clinical parameters of disease
activity including morning stiffness, visual analog scale
(VAS) scores, number of tender joints, number of swollen
joints, and Disease Activity Score 28 (DAS28) (5). Other
assessments included patient global assessment score
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(GAS) and physician GAS (6), RA health assessment
questionnaire (RA-HAQ), and RA quality of life scale
(RA-QoL) (7). A score of DAS28 of <3.2 was accepted as
mild RA, scores between 3.2 and 5.1 as moderate RA, and
scores of >5.1 as severe RA (8). A HAQ cut-off value of
≥1.5 is accepted as signifying an unsatisfactory functional
state (9).
The laboratory assessment of disease activity included
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP).
2.3. Ankylosing spondylitis
The modified New York criteria were used for the diagnosis
of AS (10). The AS forms included age, sex, duration of the
disease, drugs used for the treatment of AS, and clinical
parameters of disease activity including VAS, Schober test,
and chest expansion values. Other assessments included
the Bath Ankylosing Spondylitis Functional Index (BASFI)
(11), Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) (12), patient GAS (13), physician GAS (13), ASHAQ (14), and AS-QoL (13). The laboratory assessment of
disease activity included ESR and CRP levels. A BASDAI
score of ≥4 was accepted as signifying active disease (9).
2.4. Statistical analysis
Nominal data were expressed as mean ± standard deviation
(SD). Categorical variables were presented as numbers and
percentages.
3. Results
Demographic characteristics of the patients with RA (n
= 45) and AS (n = 45) are shown in Table 1. The maleto-female ratio was 1:3.5 for RA patients and 3.1:1.4 for
AS patients. The mean age for the patients followed with
the diagnosis of RA was much higher (53.67 ± 11.6 years,
median: 51 years) compared to patients with AS (34.13 ±
10.21 years, median: 31 years). The mean duration of the
disease for RA patients was 6.12 ± 6.4 years, the median

was 4 years, and the range was 1 month to 30 years. For the
patients with AS, the mean duration of the disease was 6.1
± 5.2 years, the median was 5 years, and the range was 1
month to 20 years.
3.1. Rheumatoid arthritis
Clinical disease activity for RA was assessed using patient
reported morning stiffness (in minutes), VAS, tender
joints and swollen joints on physical examination, and
laboratory findings including ESR and CRP. DAS28 scores
were calculated as described previously (5) (Table 2).
The mean duration of morning stiffness was 13.84 ±
28.9 min (median: 1 min, range: 0–120 min). On physical
examination, the mean number of tender joints was 8.4
± 8.6 (median: 6, range: 0–28) and the mean number of
swollen joints was 1.9 ± 2.7 (median: 1, range: 0–13). In
patients with RA, the mean ESR was 27.82 ± 11.9 mm/h
and the median was 21.5 mm/h, and 25 patients (56%) had
ESR values of over 20 mm/h at the time of data collection.
The mean CRP level was 10.32 ± 12.3 mg/L and the median
was 5 mg/L, and 20 patients (44%) had CRP of >5 mg/L at
the time of data collection. The mean DAS28 score was 4.3
± 1.6 (median: 4.4, range: 1.52–7.78) (Table 2). According
to the DAS28, 27% of RA patients had mild disease, 44%
had moderate, and 29% had severe.
3.2. Ankylosing spondylitis
Clinical disease activity for AS was assessed on physical
examination using chest expansion measurement, Schober
test, VAS, and BASDAI, and physical functioning state was
assessed by BASFI scores as described previously (11,12).
The mean chest expansion was 5.33 ± 1.8 cm (median:
5 cm, range: 1.5–9.0 cm). The mean Schober test result was
4.7 ± 1.5 cm (median: 4.5 cm, range: 1–8 cm). The mean
BASDAI score was 4.6 ± 2.3 (median: 4.6, range: 0.8–9.0),
and 64% of patients had active disease based on BASDAI
scores. The mean BASFI score was 3.29 ± 2.9 (median: 2.5,
range: 0–12.1). In patients with AS, the mean ESR was

Table 1. Demographic findings of patients with rheumatoid arthritis (RA) and
ankylosing spondylitis (AS).
RA

AS

N

45

45

Sex
(M/F)

10/35

31/14

Age (years)
Mean ± SD (median)

53.67 ± 11.6 (51)

34.13 ± 10.21 (31)

Duration (years)
Mean ± SD (median)

6.12 ± 6.4 (4)

6.11 ± 5.2 (5)

N: Number of patients, M: number of males, F: number of females.
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Table 2. Clinical and laboratory disease activity measurements of patients with RA.
Mean ± SD

Median

Range

Morning stiffness (min)

13.84 ± 28.9

1

0–120

Tender joints (N)

8.4 ± 8.6

6

0–28

Swollen joints (N)

1.85 ± 2.7

1

0–13

ESR (mm/h)*

27.82 ± 11.9

21.5

2–64

CRP (mg/L)*

10.32 ± 12.3

5

1.1–48.7

DAS28

4.3 ± 1.6

4.4

1.52–7.78

N: Number, *: based on the last values at the time of data collection.

16.54 ± 18.6 mm/h and the median was 9 mm/h, and 7
patients (16%) had ESR values of >20 mm/h at the time of
data collection. The mean CRP level was 10.07 ± 19.9 mg/L
and the median was 3 mg/L, and 7 patients (16%) had CRP
of >5 mg/L at the time of data collection (Table 3).
3.3. Physician and patient GAS
The severity of disease for both RA and AS was evaluated
using physician GAS and patient GAS as described
elsewhere (6,12,13) (Table 4). For RA, the mean physician

GAS was 4.11 ± 2.9 (median: 5, range: 0–8) and the mean
patient GAS was 4.64 ± 2.4 (median: 5, range: 0–10), and
for AS, the physician GAS was 4.8 ± 2.8 (median: 5, range:
0–10 ) and the mean patient GAS was 4.9 ± 3.1 (median:
5, range: 0–10).
3.4. HAQ and QoL
The quality of life for RA and AS patients was evaluated
using HAQ and QoL scales (Table 4). For patients with RA,
the mean HAQ score was 13.04 ± 12.9 (median: 10, range:

Table 3. Clinical and laboratory disease activity measurements of patients with AS.
Mean ± SD

Median

Range

Chest expansion (cm)

5.33 ± 1.8

5

1.5–9.0

Schober (cm)

4.7 ± 1.5

4.5

1–8

BASDAI

4.6 ± 2.3

4.6

0.8–9.0

BASFI

3.29 ± 2.9

2.5

0–12.1

ESR (mm/h)*

16.54 ± 18.6

9

1–70

CRP (mg/L)*

10.07± 19.9

3

0.4–98.7

*: Based on the last values at the time of data collection.
Table 4. Evaluation of the severity of the disease by patients and physicians and its effect
on quality of life in patients with RA and AS.
RA*

AS*		

Physician GAS

4.11 ± 2.9 (5)

4.8 ± 2.8 (5)

Patient GAS

4.64 ± 2.4 (5)

4.9 ± 3.1 (5)

HAQ

13.04 ± 12.9 (10)

3.64 ± 2.2 (3)

QoL

14.13 ± 9.1 (10)

8.91 ± 5.3 (10)

*: Values given as Mean ± SD (median), GAS: global assessment score, HAQ: health
assessment questionnaire, QoL: quality of life scale.
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0–51) and the mean QoL score was 14.13 ± 9.1 (median:
15, range: 0–30). In RA patients, 25% had a HAQ score of
<1.5 (satisfactory functional state).
For patients with AS, the mean HAQ score was 3.64 ±
2.2 (median: 3, range: 0–11) and the mean QoL score was
8.91 ± 5.3 (median: 10, range: 0–18). In AS patients, 16%
had a HAQ score of <1.5 (satisfactory functional state).
3.5. Treatment
The drugs used in patients with RA are listed in Table 5.
A high percentage (31.1%) of patients with RA were only
on nonsteroidal antiinflammatory drugs (NSAIDs). Only
a small percentage was taking a single disease-modifying
antirheumatic drug (DMARD), whereas 13.3% were taking
combined DMARDs. However, the highest percentage of
patients (35.6%) were treated with biological agents.
For AS patients, the treatment regimens used are
shown in Table 6. Twenty-four percent of patients with
AS were treated with NSAIDs and another 24% with an
NSAID-sulfasalazine combination. About 22% of patients
with AS were receiving biological agents and 13% were not
on any medication at the time of data collection.

4. Discussion
In this study, the clinical and laboratory characteristics of
the 2 most common rheumatic diseases, namely RA and
AS, were analyzed. There are a few studies reported from
Turkey about the clinical characteristics of RA and AS
(15–19). Since the sample size of this study is small, rather
than being an epidemiologic study, it represents the data
of a small sample of patients in an urban area of Turkey
treated in a tertiary care center and forms a descriptive
study.
In this study, the male-to-female ratio for RA was 1:3.5
and for AS was 3.1:1.4, both very similar to the reported
epidemiologic studies worldwide (1,3). In our crosssectional study, the mean age of patients with RA was
much higher (53.67 ± 11.6 years) compared to patients
with AS (34.13 ± 10.21 years), and this is consistent with
the natural course of the disease and the fact that RA
presents much later compared to AS in adult populations
(8).
The activity of the disease can be assessed by using
different measures including the DAS28 for RA and the

Table 5. Drugs used in treatment of patients with RA.
N

%

No drugs

4

8.9

NSAIDs*

14

31.1

Single DMARD**

1

2.2

Combined DMARDs

6

13.3

Biological agents

16

35.6

Biologic agent-DMARD combination

4

8.9

*: Nonsteroidal antiinflammatory drugs, **: disease-modifying antirheumatic drugs.

Table 6. Drugs used in treatment of patients with AS.
N

%

No drugs

6

13.3

NSAIDs*

11

24.4

Sulfasalazine

4

8.9

NSAID-sulfasalazine combination

11

24.4

Biological agent

10

22.2

Others

3

6.7

*: Nonsteroidal antiinflammatory drugs.
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BASFI and BASDAI for AS, and the functional state of the
disease can be assessed with the HAQ for both.
In our study, the percentage of patients with a DAS28
score of >3.2 (moderate to severe disease) was 73%. This
percentage is very similar to that of a study done in Turkey
with 562 patients (73.9%) in 2008 (19). According to the
HAQ scoring, which is used to evaluate the functional
state of the patients with RA, only 25% were functionally
satisfactory. This finding was in parallel to DAS28 scoring
in our study.
In patients with AS, according to the BASDAI, 64% of
patients had active disease. This percentage is similar to that
in a previous study done in Turkey (19). In AS patients, only
16% of the patients had a HAQ score of <1.5 (satisfactory
functional state). Although AS patients seem to have less
severe disease activity and better functional states compared
to RA patients, it still seems to be quite severe disease in most
cases in our study. Since this study was done in a tertiary
care center with referrals of the most severe cases, this high
percentage of severe disease affecting the functional state of
the majority of patients is not surprising.
The treatment regimen used in RA in this crosssectional study at the time of data collection included
NSAIDs, DMARDs, biologic agents, and various
combinations of these. In RA, the most common treatment
used was biological agents at a rate of 35.6%, followed
by NSAIDs alone. The use of combined DMARDs was

6 times more common compared to the use of a single
DMARD. Previous studies show that the most common
treatment prescribed is DMARDs, at a rate of 72%–93%
(19,20). The discrepancy between our data and the data
in the literature may be due to biological agents being
more widely available in our country in the past 10 years.
Another finding noted was that the percentage of patients
on NSAIDs alone seems to be quite high, which may be
due to the fact that the patients who are on NSAIDs are
more frequently referred to our tertiary center due to
inadequate control of the disease with NSAIDs alone.
In our study, the most common treatments prescribed
for AS patients included NSAIDs alone and the NSAIDsulfasalazine combination (24.4% each). In contrast to a
previous study in Turkey (19), none of our patients were
on methotrexate treatment since recent studies have
shown that it is ineffective in modifying the course of the
disease (21). The second most common treatment regimen
was biological agents at 22.2%. About 13% of the patients
were not on any medications due to either noncompliance/
patient preference or due to inactive disease.
In conclusion, in our tertiary care center, the majority
of patients with RA and AS had active disease with
unsatisfactory functional state. Investigating the reasons
for the high rate of active disease in a tertiary care center is
worthwhile, and this would be helpful in defining new and
better strategies in the control of these diseases.
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